Pfizer and Novavax
Type: License agreement
In-Licensee: Pfizer
Out-Licensor: Novavax
Focus: Matrix-M® adjuvant
Upfront Payment: $30 million
Milestone Payment: $500 million
Financial impact: The agreement helped Novavax turn profitable, generating $440 million in net income in 2025, up from a loss the previous year, driven by increased licensing and partnership revenue.
Novavax posted a $440 million net profit in 2025, up from a loss in 2024, driven by a 65% revenue jump to $1.1 billion and strategic licensing deals with Pfizer and Sanofi. The company’s shift from direct vaccine sales to monetizing its Matrix‑M adjuvant technology, including a Pfizer deal with $30 million upfront and up to $500 million in milestones plus royalties, marked a major financial turnaround.
Matrix-M® adjuvant
Matrix-M™ is a saponin-based adjuvant used in several vaccine candidates, including Novavax’s COVID-19 vaccine NVX-CoV2373. It combines purified saponins from the Quillaja saponaria tree with cholesterol and phospholipids to form 40-nm nanoparticles, enhancing immune responses while maintaining a favorable safety profile. Matrix-M activates innate immune cells at the injection site and lymph nodes, boosting antibody magnitude, epitope breadth, and Th1-dominant immunity.
Biodistribution studies in mice showed rapid localization of saponins and cholesterol to the injection site and draining lymph nodes, with saponins cleared within 48–72 hours and cholesterol entering the body’s recycling pool. Systemic exposure to other tissues was minimal, supporting its safety. These findings indicate Matrix-M’s mechanism relies on local immune activation rather than a depot effect, contributing to potent and well-tolerated adaptive immune responses.
Eleven years' market revenue of Novavax
Novavax’s revenue has fluctuated significantly over the past decade. The company reported $15.35–$15.4 million in 2016, down 58% from 2015, primarily due to reduced HHS BARDA contract revenue. Revenue declines continued in 2018–2019, driven by completion of clinical trials and lower development activity for ResVax, though NanoFlu development partially offset these decreases. R&D and administrative expenses were gradually reduced, while cash reserves declined to $82.2 million by the end of 2019, down from $103.9 million in 2018.
Eleven years market revenue of Novavax (2015-2025)
Fig 5: Market revenue of Novavax
In 2020, Novavax’s cash position surged to $806.4 million through At-the-Market offerings and a private placement, while net cash used in operations fell to $42.5 million. Revenue grew sharply in 2021 and 2022 with Nuvaxovid product sales, reaching $1.1 billion and $1.9 billion, respectively. This marked Novavax’s transition to a commercial-stage company.
Revenue declined in 2024 to $682 million for the full year, with product sales falling to $190 million, reflecting lower sales under APA agreements. In 2025, total revenue rebounded to $1.123 billion, up 65% from 2024, driven by $625 million in Nuvaxovid sales, mostly associated with prior-year Advance Purchase Agreements.
“The Pfizer-Novavax licensing deal boosted investor confidence, validated Matrix‑M technology, and opened the door to long-term revenue and strategic partnerships.”
Market Impact of This Partnership
The licensing agreement between Pfizer and Novavax positively impacted the market by boosting investor confidence and lifting Novavax’s share price. The deal, which included a $30 million upfront payment plus up to $500 million in milestones and royalties, strengthened Novavax’s financial outlook and validated the value of its Matrix‑M adjuvant technology. By shifting focus toward technology licensing, the agreement highlighted long-term revenue potential and positioned Novavax for additional partnerships and diversified income streams.